Page last updated: 2024-11-09

hypocrellin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hypocrellin B: photosensitive pigments isolated from Hypocrella bambusae Sacc; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1023768
CHEMBL ID2029624
CHEMBL ID4793204
SCHEMBL ID14302232
SCHEMBL ID13121633
MeSH IDM0177679

Synonyms (22)

Synonym
hypocrellin c
hypocrellin b
CHEMBL2029624
123940-54-5
SCHEMBL14302232
APTUSGMALOMQQL-UHFFFAOYSA-N
SCHEMBL13121633
149457-83-0
shiraiachrome c
(e)-13-acetyl-3,8-dihydroxy-1,5,6,10-tetramethoxy-12-methyl-2h-cyclohepta[ghi]perylene-2,9(11h)-dione
AKOS037514883
mfcd00467741
1h-cyclohepta[ghi]perylene-6,11-dione,3-acetyl-5,12-dihydroxy-4,8,9,13-tetramethoxy-2-methyl-
CHEMBL4793204
CS-0032509
HY-N6081
HY-N1453
CS-0016899
12-acetyl-9,17-dihydroxy-5,10,16,21-tetramethoxy-13-methylhexacyclo[13.8.0.02,11.03,8.04,22.018,23]tricosa-1(15),2(11),3(8),4(22),5,9,12,16,18(23),20-decaene-7,19-dione
YEA94054
AKOS040760459
FS-7755

Research Excerpts

Overview

Hypocrellin B (HB) is a natural pigment with a promising application in the photodynamic therapy (PDT) for anticancer treatment.

ExcerptReferenceRelevance
"Hypocrellin B (HB) is a natural perylene quinone photosensitizer."( Effects of Photodynamic Therapy Using Yellow LED-light with Concomitant Hypocrellin B on Apoptotic Signaling in Keloid Fibroblasts.
Han, G; Hu, Y; Jiao, Y; Li, S; Qi, T; Wei, G; Zhang, C, 2017
)
1.41
"Hypocrellin B (HB) is a natural pigment with a promising application in the photodynamic therapy (PDT) for anticancer treatment. "( Investigation of photobleaching of hypocrellin B in non-polar organic solvent and in liposome suspension.
Chen, S; Shen, T; Xu, S; Yu, C; Zhang, M, 2002
)
2.03
"The Hypocrellin B (HB) is a new photosensitizer. "( [Hypocrellin B photosensitization effected a change of cytoplasmic free calcium concentration in ascitic hepatoma cells].
Pang, SZ; Yue, JC; Zhang, L, 1993
)
1.75

Toxicity

ExcerptReferenceRelevance
" These data collectively indicate that LHB may be a safe and effective photosensitizer for vascular-targeted PDT of AMD."( Liposomal hypocrellin B as a potential photosensitizer for age-related macular degeneration: pharmacokinetics, photodynamic efficacy, and skin phototoxicity in vivo.
Chen, H; Deng, H; Gu, Y; Hou, X; Huang, N; Li, T; Zeng, J; Zhao, J, 2015
)
0.82

Bioavailability

ExcerptReferenceRelevance
" Tumor response detected at low light dose (12 J/cm(2); 12 mW/cm(2)) at short DLI suggests that the tumor vasculature is a more sensitive target compared to the cellular compartment of the tumor, correlating significantly with the bioavailability of the drug in serum."( Evaluation of Hypocrellin B in a human bladder tumor model in experimental photodynamic therapy: biodistribution, light dose and drug-light interval effects.
Cheng, C; Chin, W; Lau, W; Olivo, M, 2004
)
0.68
" Both the DNA binding constants and photo nuclease activities of the complexes follow the order 2 (tmp) > 3 (dpq) > 1 (phen), demonstrating the importance of the binding affinity to biomolecules, which improves the bioavailability of reactive oxygen species."( Oxovanadium(IV) based hypocrellin B complexes with enhanced photodynamic activity.
Hou, YJ; Lei, WH; Sun, Y; Wang, XS; Zhang, BW; Zheng, Y; Zhou, QX, 2012
)
0.69
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID662909Photosensitization activity of the compound assessed as singlet oxygen production by DPA-bleaching method2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Quantitative and site-directed chemical modification of hypocrellins toward direct drug delivery and effective photodynamic activity.
AID662905Drug uptake in liposomes after 5 hrs2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Quantitative and site-directed chemical modification of hypocrellins toward direct drug delivery and effective photodynamic activity.
AID662907Solubility of the compound in phosphate buffered saline at pH 7.4 after 12 hrs2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Quantitative and site-directed chemical modification of hypocrellins toward direct drug delivery and effective photodynamic activity.
AID662913Cytotoxicity against human BGC823 cells assessed as cell death preincubated for 5 hrs in dark condition followed by irradiation with a 532 nm laser of 20 J/cm2 for 1000 seconds measured after 24 hrs by MTT assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Quantitative and site-directed chemical modification of hypocrellins toward direct drug delivery and effective photodynamic activity.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID662912Cytotoxicity against human BGC823 cells assessed as cell death up to 76 nM after 24 hrs by MTT assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Quantitative and site-directed chemical modification of hypocrellins toward direct drug delivery and effective photodynamic activity.
AID6629081-Octanol-phosphate buffered saline partition coefficient, log P of the compound at pH 7.42012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Quantitative and site-directed chemical modification of hypocrellins toward direct drug delivery and effective photodynamic activity.
AID1696497Phototoxicity against human SK-MEL-28 cells assessed as reduction in cell viability preincubated for 16 hrs followed by irradiated with 100 J/cm2 400 to 700 nanometer visible light for 40 mins and measured after 48 hrs by alamar blue assay2020Journal of natural products, 08-28, Volume: 83, Issue:8
Enhanced Production and Anticancer Properties of Photoactivated Perylenequinones.
AID1696498Phototherapeutic index, ratio of EC50 for cytotoxicity against human SK-MEL-28 cells in dark condition to EC50 for phototoxicity against human SK-MEL-28 cells preincubated for 16 hrs followed by irradiated with 100 J/cm2 400 to 700 nanometer visible light2020Journal of natural products, 08-28, Volume: 83, Issue:8
Enhanced Production and Anticancer Properties of Photoactivated Perylenequinones.
AID1696499Phototoxicity against human SK-MEL-28 cells assessed as reduction in cell viability preincubated for 16 hrs followed by irradiated with 100 J/cm2 625 nanometer red light for 60 mins and measured after 48 hrs by alamar blue assay2020Journal of natural products, 08-28, Volume: 83, Issue:8
Enhanced Production and Anticancer Properties of Photoactivated Perylenequinones.
AID1696500Phototherapeutic index, ratio of EC50 for cytotoxicity against human SK-MEL-28 cells in dark condition to EC50 for phototoxicity against human SK-MEL-28 cells preincubated for 16 hrs followed by irradiated with 100 J/cm2 625 nanometer red light for 60 min2020Journal of natural products, 08-28, Volume: 83, Issue:8
Enhanced Production and Anticancer Properties of Photoactivated Perylenequinones.
AID1696496Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability preincubated for 16 hrs in dark condition subsequently incubated for 48 hrs by alamar blue assay2020Journal of natural products, 08-28, Volume: 83, Issue:8
Enhanced Production and Anticancer Properties of Photoactivated Perylenequinones.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (118)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's17 (14.41)18.2507
2000's42 (35.59)29.6817
2010's48 (40.68)24.3611
2020's11 (9.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.01 (24.57)
Research Supply Index4.80 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index27.14 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (1.65%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other119 (98.35%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]